A phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

EUDRA-CT number:2016-003472-52


Study sites:

  • UZ Leuven, Leuven
  • UZ Gent, Gent
  • AZ Maria Middelares, Gent
  • Cliniques Universitaires Saint-Luc, Woluwe Saint-Lambert
  • CHC-Clinique Saint-Joseph, Liège
  • GZA Sint-Augustinus, Wilrijk
  • AZ Turnhout, Turnhout
  • Ziekenhuis Oost-Limburg, Genk